What is SanegeneBio?
Founded in 2021, SanegeneBio is a fully-integrated biotechnology enterprise dedicated to the advancement of RNAi-based medicines. The company operates at the intersection of cutting-edge molecular biology and clinical pharmacology, utilizing its industry-leading LEAD delivery platform to enhance the precision and efficacy of therapeutic interventions. With a leadership team comprised of seasoned RNAi experts, the organization maintains a robust R&D footprint that spans international borders, facilitating a collaborative approach to drug discovery. SanegeneBio's market position is defined by its focus on high-impact therapeutic areas, aiming to transform the standard of care for patients suffering from complex chronic diseases through innovative, tissue-specific genetic modulation.
How much funding has SanegeneBio raised?
SanegeneBio has raised a total of $110M across 1 funding round:
Series B
$110M
Series B (2025): $110M with participation from Legend Capital, Lilly, Hillhouse, and China Biopharma
Key Investors in SanegeneBio
Legend Capital
Legend Capital is a prominent private equity firm with a long-standing history of supporting innovation and growth-stage enterprises, particularly those with significant operations in the Chinese market.
Lilly
Eli Lilly and Company is a global biopharmaceutical leader focused on research-driven innovation across critical therapeutic areas including diabetes, oncology, and immunology.
Hillhouse
Hillhouse is a full life-cycle private equity firm that manages capital for global institutions, with a strong emphasis on long-term value creation within the healthcare and life sciences sectors.
What's next for SanegeneBio?
Looking ahead, SanegeneBio is poised to leverage its recent financing to scale its clinical operations and broaden its therapeutic reach. The strategic roadmap involves the continued progression of its pipeline, with a specific emphasis on achieving key clinical milestones for its lead candidates. By maintaining a focus on its proprietary delivery technology, the company aims to solidify its competitive advantage in the biopharmaceutical landscape. Future growth will likely be characterized by increased investment in manufacturing capabilities and potential strategic partnerships to facilitate the commercialization of its experimental medicines. As the company matures, its ability to navigate the regulatory environment while maintaining a high velocity of innovation will be paramount to its long-term success in the global biotechnology market.
See full SanegeneBio company page
